{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T02:38:25Z","timestamp":1786502305572,"version":"build-2736575974"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The poor prognosis of bladder cancer (BCa) is primarily attributed to the acquisition of invasive and metastatic capabilities by tumor cells through epithelial-mesenchymal transition (EMT), yet the dynamic alterations in ferroptosis during EMT and their regulatory mechanisms remain unelucidated. This study is the first to reveal the mechanism by which the Smad3\/CISD2 signaling axis regulates ferroptosis in mesenchymal-like bladder cancer cells. Clinical sample analysis demonstrated significantly reduced expression of E-cadherin and upregulation of N-cadherin and Vimentin in muscle-invasive bladder cancer tissues (MIBC), with EMT-related marker levels correlating with overall survival rates in BCa patients. In TGF-\u03b21-induced mesenchymal-like bladder cancer cells, ferroptosis-related genes (GPX4, SLC7A11) were markedly elevated, alongside increased lipid peroxides (LPO) and glutathione (GSH) levels. However, mesenchymal-like bladder cancer cells exhibited heightened sensitivity to the ferroptosis inducer Erastin, showing more pronounced suppression of proliferation, elevated ROS, higher LPO and MDA levels, and reduced GSH, confirming their enhanced susceptibility to ferroptosis. RNA-seq revealed significant downregulation of Smad3 in ferroptosis inducer treated mesenchymal-like bladder cancer cells. Smad3 knockdown further exacerbated ferroptosis markers (elevated Fe\u00b2\u207a, ROS, LPO; decreased GSH), inhibited migration, invasion, and proliferation\u2014phenotypes reversible by ferroptosis inhibitors. Mechanistically, ChIP-seq combined with RNA-seq demonstrated that Smad3 regulates CISD2 expression by binding its promoter region, with clinical specimens confirming a positive correlation between Smad3 and CISD2 expression. Functional rescue experiments showed that CISD2 overexpression in Smad3-knockdown mesenchymal-like bladder cancer cells reversed abnormal increases in Fe\u00b2\u207a, ROS, LPO, and MDA while restoring GSH levels, indicating that Smad3 modulates ferroptosis through a CISD2-dependent pathway. In vivo experiments further demonstrated that targeting the Smad3\/CISD2 axis significantly suppressed xenograft tumor growth and activated ferroptosis. In conclusion, this study elucidates a novel mechanism by which the Smad3\/CISD2 axis dynamically regulates ferroptosis through redox homeostasis reprogramming during EMT, providing a potential therapeutic strategy for targeting the progression of MIBC.<\/jats:p>","DOI":"10.1038\/s41419-025-08339-9","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T19:13:54Z","timestamp":1766085234000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Targeting the SMAD3\/CISD2 axis suppresses bladder cancer progression by promoting ferroptosis in mesenchymal-like bladder cancer cells"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-1852-3818","authenticated-orcid":false,"given":"Yulin","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianghui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9908-7171","authenticated-orcid":false,"given":"Da","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanmin","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinpeng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6406-7173","authenticated-orcid":false,"given":"Zilian","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5190-5817","authenticated-orcid":false,"given":"Weiting","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"8339_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA: Cancer J Clin"},{"key":"8339_CR2","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk M, Burger M, Capoun O, Cohen D, Comp\u00e9rat EM, Dominguez Escrig JL, et al. European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol. 2022;81:75\u201394.","journal-title":"Eur Urol"},{"key":"8339_CR3","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","volume":"79","author":"JA Witjes","year":"2021","unstructured":"Witjes JA, Bruins HM, Cathomas R, Comp\u00e9rat EM, Cowan NC, Gakis G, et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. Eur Urol. 2021;79:82\u2013104.","journal-title":"Eur Urol"},{"key":"8339_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2023.100938","volume":"68","author":"F Li","year":"2023","unstructured":"Li F, Zheng Z, Chen W, Li D, Zhang H, Zhu Y, et al. Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms. Drug Resist Updates: Rev Commentaries Antimicrob Anticancer Chemother. 2023;68:100938.","journal-title":"Drug Resist Updates: Rev Commentaries Antimicrob Anticancer Chemother"},{"key":"8339_CR5","doi-asserted-by":"publisher","first-page":"216","DOI":"10.6004\/jnccn.2024.0024","volume":"22","author":"TW Flaig","year":"2024","unstructured":"Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Buyyounouski MK, et al. NCCN Guidelines\u00ae insights: bladder cancer, version 3.2024. J Natl Compr Cancer Netw. 2024;22:216\u201325.","journal-title":"J Natl Compr Cancer Netw"},{"key":"8339_CR6","first-page":"e076743","volume":"384","author":"A Lopez-Beltran","year":"2024","unstructured":"Lopez-Beltran A, Cookson MS, Guercio BJ, Cheng L. Advances in diagnosis and treatment of bladder cancer. BMJ (Clin Res ed). 2024;384:e076743.","journal-title":"BMJ (Clin Res ed)"},{"key":"8339_CR7","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13045-022-01347-8","volume":"15","author":"Y Huang","year":"2022","unstructured":"Huang Y, Hong W, Wei X. The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis. J Hematol Oncol. 2022;15:129.","journal-title":"J Hematol Oncol"},{"key":"8339_CR8","volume":"76","author":"J Guo","year":"2024","unstructured":"Guo J, Ma X, Liu D, Wang F, Xia J, Zhang B, et al. A distinct subset of urothelial cells with enhanced EMT features promotes chemotherapy resistance and cancer recurrence by increasing COL4A1-ITGB1 mediated angiogenesis. Drug Resist Updates Rev Commentaries Antimicrob Anticancer Chemother. 2024;76:101116.","journal-title":"Drug Resist Updates Rev Commentaries Antimicrob Anticancer Chemother"},{"key":"8339_CR9","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41580-020-0237-9","volume":"21","author":"J Yang","year":"2020","unstructured":"Yang J, Antin P, Berx G, Blanpain C, Brabletz T, Bronner M, et al. Guidelines and definitions for research on epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2020;21:341\u201352.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"8339_CR10","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41419-023-05880-3","volume":"14","author":"S Xi","year":"2023","unstructured":"Xi S, Ming DJ, Zhang JH, Guo MM, Wang SY, Cai Y, et al. Downregulation of N6-methyladenosine-modified LINC00641 promotes EMT, but provides a ferroptotic vulnerability in lung cancer. Cell Death Dis. 2023;14:359.","journal-title":"Cell Death Dis"},{"key":"8339_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2021.102149","volume":"47","author":"T Oliveira","year":"2021","unstructured":"Oliveira T, Hermann E, Lin D, Chowanadisai W, Hull E, Montgomery M. HDAC inhibition induces EMT and alterations in cellular iron homeostasis to augment ferroptosis sensitivity in SW13 cells. Redox Biol. 2021;47:102149.","journal-title":"Redox Biol"},{"key":"8339_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01897-6","volume":"22","author":"K Komura","year":"2023","unstructured":"Komura K, Hirosuna K, Tokushige S, Tsujino T, Nishimura K, Ishida M, et al. The impact of FGFR3 alterations on the tumor microenvironment and the efficacy of immune checkpoint inhibitors in bladder cancer. Mol Cancer. 2023;22:185.","journal-title":"Mol Cancer"},{"key":"8339_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-020-00741-6","volume":"12","author":"HW Lee","year":"2020","unstructured":"Lee HW, Chung W, Lee HO, Jeong DE, Jo A, Lim JE, et al. Single-cell RNA sequencing reveals the tumor microenvironment and facilitates strategic choices to circumvent treatment failure in a chemorefractory bladder cancer patient. Genome Med. 2020;12:47.","journal-title":"Genome Med"},{"key":"8339_CR14","doi-asserted-by":"publisher","first-page":"100094","DOI":"10.59717\/j.xinn-med.2024.100094","volume":"2","author":"X Lu","year":"2024","unstructured":"Lu X, Cheng L, Yang C, Huang J, Chen X. Crosstalk between bladder cancer and the tumor microenvironment: Molecular mechanisms and targeted therapy. Innov Med. 2024;2:100094.","journal-title":"Innov Med"},{"key":"8339_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2021.109932","volume":"81","author":"H Shi","year":"2021","unstructured":"Shi H, Xie J, Wang K, Li W, Yin L, Wang G, et al. LINC01451 drives epithelial-mesenchymal transition and progression in bladder cancer cells via LIN28\/TGF-\u03b2\/Smad pathway. Cell Signal. 2021;81:109932.","journal-title":"Cell Signal"},{"key":"8339_CR16","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.ccell.2024.03.011","volume":"42","author":"G Lei","year":"2024","unstructured":"Lei G, Zhuang L, Gan B. The roles of ferroptosis in cancer: Tumor suppression, tumor microenvironment, and therapeutic interventions. Cancer Cell. 2024;42:513\u201334.","journal-title":"Cancer Cell"},{"key":"8339_CR17","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/s41392-024-01969-z","volume":"9","author":"Q Ru","year":"2024","unstructured":"Ru Q, Li Y, Chen L, Wu Y, Min J, Wang F. Iron homeostasis and ferroptosis in human diseases: mechanisms and therapeutic prospects. Signal Transduct Target Ther. 2024;9:271.","journal-title":"Signal Transduct Target Ther"},{"key":"8339_CR18","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41392-024-01769-5","volume":"9","author":"Q Zhou","year":"2024","unstructured":"Zhou Q, Meng Y, Li D, Yao L, Le J, Liu Y, et al. Ferroptosis in cancer: from molecular mechanisms to therapeutic strategies. Signal Transduct Target Ther. 2024;9:55.","journal-title":"Signal Transduct Target Ther"},{"key":"8339_CR19","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1038\/s41556-024-01483-y","volume":"26","author":"AM Winkelkotte","year":"2024","unstructured":"Winkelkotte AM, Schulze A. A fatty acid switch drives ferroptosis in EMT. Nat Cell Biol. 2024;26:1375\u20136.","journal-title":"Nat Cell Biol"},{"key":"8339_CR20","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1038\/s41556-024-01464-1","volume":"26","author":"A Schwab","year":"2024","unstructured":"Schwab A, Rao Z, Zhang J, Gollowitzer A, Siebenk\u00e4s K, Bindel N, et al. Zeb1 mediates EMT\/plasticity-associated ferroptosis sensitivity in cancer cells by regulating lipogenic enzyme expression and phospholipid composition. Nat Cell Biol. 2024;26:1470\u201381.","journal-title":"Nat Cell Biol"},{"key":"8339_CR21","doi-asserted-by":"crossref","unstructured":"Wei X, Ge Y, Zheng Y, Zhao S, Zhou Y, Chang Y, et al. Hybrid EMT phenotype and cell membrane tension promote colorectal cancer resistance to ferroptosis. Adv Sci. 2025:e2413882.","DOI":"10.1002\/advs.202413882"},{"key":"8339_CR22","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41422-022-00642-w","volume":"32","author":"R Yan","year":"2022","unstructured":"Yan R, Xie E, Li Y, Li J, Zhang Y, Chi X, et al. The structure of erastin-bound xCT-4F2hc complex reveals molecular mechanisms underlying erastin-induced ferroptosis. Cell Res. 2022;32:687\u201390.","journal-title":"Cell Res"},{"key":"8339_CR23","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41580-024-00703-5","volume":"25","author":"SJ Dixon","year":"2024","unstructured":"Dixon SJ, Olzmann JA. The cell biology of ferroptosis. Nat Rev Mol Cell Biol. 2024;25:424\u201342.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"8339_CR24","doi-asserted-by":"publisher","first-page":"4045","DOI":"10.1016\/j.apsb.2021.03.036","volume":"11","author":"N Kong","year":"2021","unstructured":"Kong N, Chen X, Feng J, Duan T, Liu S, Sun X, et al. Baicalin induces ferroptosis in bladder cancer cells by downregulating FTH1. Acta Pharm Sin B. 2021;11:4045\u201354.","journal-title":"Acta Pharm Sin B"},{"key":"8339_CR25","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","volume":"22","author":"X Jiang","year":"2021","unstructured":"Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021;22:266\u201382.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"8339_CR26","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13045-019-0720-y","volume":"12","author":"Y Mou","year":"2019","unstructured":"Mou Y, Wang J, Wu J, He D, Zhang C, Duan C, et al. Ferroptosis, a new form of cell death: opportunities and challenges in cancer. J Hematol Oncol. 2019;12:34.","journal-title":"J Hematol Oncol"},{"key":"8339_CR27","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1089\/ars.2018.7502","volume":"30","author":"R Mittler","year":"2019","unstructured":"Mittler R, Darash-Yahana M, Sohn YS, Bai F, Song L, Cabantchik IZ, et al. NEET proteins: a new link between iron metabolism, reactive oxygen species, and cancer. Antioxid Redox Signal. 2019;30:1083\u201395.","journal-title":"Antioxid Redox Signal"},{"key":"8339_CR28","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.eururo.2016.06.010","volume":"71","author":"S Antoni","year":"2017","unstructured":"Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017;71:96\u2013108.","journal-title":"Eur Urol"},{"key":"8339_CR29","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1056\/NEJMoa1106106","volume":"366","author":"ND James","year":"2012","unstructured":"James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012;366:1477\u201388.","journal-title":"N Engl J Med"},{"key":"8339_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.685","volume":"5","author":"L Cheng","year":"2024","unstructured":"Cheng L, Yang C, Lu J, Huang M, Xie R, Lynch S, et al. Oncogenic SLC2A11-MIF fusion protein interacts with polypyrimidine tract binding protein 1 to facilitate bladder cancer proliferation and metastasis by regulating mRNA stability. MedComm. 2024;5:e685.","journal-title":"MedComm"},{"key":"8339_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.216023","volume":"554","author":"X Meng","year":"2023","unstructured":"Meng X, Xiao W, Sun J, Li W, Yuan H, Yu T, et al. CircPTK2\/PABPC1\/SETDB1 axis promotes EMT-mediated tumor metastasis and gemcitabine resistance in bladder cancer. Cancer Lett. 2023;554:216023.","journal-title":"Cancer Lett"},{"key":"8339_CR32","doi-asserted-by":"publisher","first-page":"0735","DOI":"10.34133\/research.0735","volume":"8","author":"C Zhang","year":"2025","unstructured":"Zhang C, Liu S, Zhang J, Lu J, Chen Z, Pan B, et al. A multifunctional Fe-EGCG@RSL3 nanomedicine synergizes ferroptosis induction and tumor microenvironment remodeling for enhanced bladder cancer immunotherapy. Research. 2025;8:0735.","journal-title":"Research"},{"key":"8339_CR33","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.jconrel.2023.11.050","volume":"365","author":"C Ma","year":"2024","unstructured":"Ma C, Zhong X, Liu R, Yang X, Xie Z, Zhang Y, et al. Co-delivery of oxaliplatin prodrug liposomes with Bacillus Calmette-Gu\u00e9rin for chemo-immunotherapy of orthotopic bladder cancer. J Control Release. 2024;365:640\u201353.","journal-title":"J Control Release"},{"key":"8339_CR34","doi-asserted-by":"crossref","unstructured":"Wang H, Zhan H, Pan B, Zeng L, Chen Z, Liu S, et al. Engineering CRISPR system-based bacterial outer membrane vesicle potentiates t cell immunity for enhanced cancer immunotherapy. Adv Mater. 2025:e2501565.","DOI":"10.1002\/adma.202501565"},{"key":"8339_CR35","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.jconrel.2023.09.024","volume":"363","author":"Q Ding","year":"2023","unstructured":"Ding Q, Tang W, Li X, Ding Y, Chen X, Cao W, et al. Mitochondrial-targeted brequinar liposome boosted mitochondrial-related ferroptosis for promoting checkpoint blockade immunotherapy in bladder cancer. J Control Release. 2023;363:221\u201334.","journal-title":"J Control Release"},{"key":"8339_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7150\/ijbs.77181","volume":"19","author":"S Monteiro-Reis","year":"2023","unstructured":"Monteiro-Reis S, Miranda-Gon\u00e7alves V, Guimar\u00e3es-Teixeira C, Martins-Lima C, Lobo J, Montezuma D, et al. Vimentin epigenetic deregulation in Bladder Cancer associates with acquisition of invasive and metastatic phenotype through epithelial-to-mesenchymal transition. Int J Biol Sci. 2023;19:1\u201312.","journal-title":"Int J Biol Sci"},{"key":"8339_CR37","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.canlet.2021.02.010","volume":"505","author":"S Liu","year":"2021","unstructured":"Liu S, Chen X, Lin T. Lymphatic metastasis of bladder cancer: molecular mechanisms, diagnosis and targeted therapy. Cancer Lett. 2021;505:13\u201323.","journal-title":"Cancer Lett"},{"key":"8339_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05938-2","volume":"14","author":"K Xiao","year":"2023","unstructured":"Xiao K, Peng S, Lu J, Zhou T, Hong X, Chen S, et al. UBE2S interacting with TRIM21 mediates the K11-linked ubiquitination of LPP to promote the lymphatic metastasis of bladder cancer. Cell Death Dis. 2023;14:408.","journal-title":"Cell Death Dis"},{"key":"8339_CR39","doi-asserted-by":"publisher","first-page":"3986","DOI":"10.7150\/ijbs.98772","volume":"20","author":"J Wu","year":"2024","unstructured":"Wu J, Huang M, Dong W, Chen Y, Zhou Q, Zhang Q, et al. SUMO E3 ligase MUL1 inhibits lymph node metastasis of bladder cancer by mediating mitochondrial HSPA9 translocation. Int J Biol Sci. 2024;20:3986\u20134006.","journal-title":"Int J Biol Sci"},{"key":"8339_CR40","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.cytogfr.2022.01.006","volume":"64","author":"N Ebrahimi","year":"2022","unstructured":"Ebrahimi N, Adelian S, Shakerian S, Afshinpour M, Chaleshtori SR, Rostami N, et al. Crosstalk between ferroptosis and the epithelial-mesenchymal transition: implications for inflammation and cancer therapy. Cytokine Growth Factor Rev. 2022;64:33\u201345.","journal-title":"Cytokine Growth Factor Rev"},{"key":"8339_CR41","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41580-024-00730-2","volume":"25","author":"H Sies","year":"2024","unstructured":"Sies H, Mailloux RJ, Jakob U. Fundamentals of redox regulation in biology. Nat Rev Mol Cell Biol. 2024;25:701\u201319.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"8339_CR42","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.semcancer.2025.02.013","volume":"112","author":"W Guo","year":"2025","unstructured":"Guo W, Duan Z, Wu J, Zhou BP. Epithelial-mesenchymal transition promotes metabolic reprogramming to suppress ferroptosis. Semin Cancer Biol. 2025;112:20\u201335.","journal-title":"Semin Cancer Biol"},{"key":"8339_CR43","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41586-019-1426-6","volume":"572","author":"J Wu","year":"2019","unstructured":"Wu J, Minikes AM, Gao M, Bian H, Li Y, Stockwell BR, et al. Intercellular interaction dictates cancer cell ferroptosis via NF2-YAP signalling. Nature. 2019;572:402\u20136.","journal-title":"Nature"},{"key":"8339_CR44","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1146\/annurev-pathmechdis-051222-122423","volume":"19","author":"R Fontana","year":"2024","unstructured":"Fontana R, Mestre-Farrera A, Yang J. Update on epithelial-mesenchymal plasticity in cancer progression. Annu Rev Pathol. 2024;19:133\u201356.","journal-title":"Annu Rev Pathol"},{"key":"8339_CR45","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.tcb.2018.12.001","volume":"29","author":"I Pastushenko","year":"2019","unstructured":"Pastushenko I, Blanpain C. EMT Transition states during tumor progression and metastasis. Trends Cell Biol. 2019;29:212\u201326.","journal-title":"Trends Cell Biol"},{"key":"8339_CR46","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1073\/pnas.1815345116","volume":"116","author":"F Bocci","year":"2019","unstructured":"Bocci F, Gearhart-Serna L, Boareto M, Ribeiro M, Ben-Jacob E, Devi GR, et al. Toward understanding cancer stem cell heterogeneity in the tumor microenvironment. Proc Natl Acad Sci USA. 2019;116:148\u201357.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8339_CR47","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41556-018-0062-y","volume":"20","author":"HW Yeh","year":"2018","unstructured":"Yeh HW, Hsu EC, Lee SS, Lang YD, Lin YC, Chang CY, et al. PSPC1 mediates TGF-\u03b21 autocrine signalling and Smad2\/3 target switching to promote EMT, stemness and metastasis. Nat Cell Biol. 2018;20:479\u201391.","journal-title":"Nat Cell Biol"},{"key":"8339_CR48","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1038\/ncb1905","volume":"11","author":"T Vincent","year":"2009","unstructured":"Vincent T, Neve EP, Johnson JR, Kukalev A, Rojo F, Albanell J, et al. A SNAIL1-SMAD3\/4 transcriptional repressor complex promotes TGF-beta mediated epithelial-mesenchymal transition. Nat Cell Biol. 2009;11:943\u201350.","journal-title":"Nat Cell Biol"},{"key":"8339_CR49","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.ccr.2006.04.025","volume":"9","author":"YA Yang","year":"2006","unstructured":"Yang YA, Zhang GM, Feigenbaum L, Zhang YE. Smad3 reduces susceptibility to hepatocarcinoma by sensitizing hepatocytes to apoptosis through downregulation of Bcl-2. Cancer Cell. 2006;9:445\u201357.","journal-title":"Cancer Cell"},{"key":"8339_CR50","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202404083","volume":"12","author":"H Han","year":"2025","unstructured":"Han H, Zhang C, Shi W, Wang J, Zhao W, Du Y, et al. NSUN5 Facilitates Hepatocellular Carcinoma Progression by Increasing SMAD3 Expression. Adv Sci. 2025;12:e2404083.","journal-title":"Adv Sci"},{"key":"8339_CR51","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s11658-022-00383-z","volume":"27","author":"Y Li","year":"2022","unstructured":"Li Y, Xu B, Ren X, Wang L, Xu Y, Zhao Y, et al. Inhibition of CISD2 promotes ferroptosis through ferritinophagy-mediated ferritin turnover and regulation of p62-Keap1-NRF2 pathway. Cell Mol Biol Lett. 2022;27:81.","journal-title":"Cell Mol Biol Lett"},{"key":"8339_CR52","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.canlet.2018.06.018","volume":"432","author":"EH Kim","year":"2018","unstructured":"Kim EH, Shin D, Lee J, Jung AR, Roh JL. CISD2 inhibition overcomes resistance to sulfasalazine-induced ferroptotic cell death in head and neck cancer. Cancer Lett. 2018;432:180\u201390.","journal-title":"Cancer Lett"},{"key":"8339_CR53","doi-asserted-by":"publisher","first-page":"3791","DOI":"10.18632\/oncotarget.6302","volume":"7","author":"L Wang","year":"2016","unstructured":"Wang L, Ouyang F, Liu X, Wu S, Wu HM, Xu Y, et al. Overexpressed CISD2 has prognostic value in human gastric cancer and promotes gastric cancer cell proliferation and tumorigenesis via AKT signaling pathway. Oncotarget. 2016;7:3791\u2013805.","journal-title":"Oncotarget"},{"key":"8339_CR54","first-page":"13725","volume":"8","author":"B Chen","year":"2015","unstructured":"Chen B, Shen S, Wu J, Hua Y, Kuang M, Li S, et al. CISD2 associated with proliferation indicates negative prognosis in patients with hepatocellular carcinoma. Int J Clin Exp Pathol. 2015;8:13725\u201338.","journal-title":"Int J Clin Exp Pathol"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08339-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08339-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08339-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T18:02:54Z","timestamp":1769536974000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08339-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8339"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-08339-9","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"assertion":[{"value":"9 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study protocol was approved by the Ethics Committee of Shandong Provincial Hospital. All experiments were performed in compliance with the relevant regulations, and all patients provided written informed consent. Besides, the animal studies were approved by the Animal Ethics Committee of Shandong Provincial Hospital. The experiments followed the Guide for the Care and Use of Laboratory Animals issued by the Chinese Council on Animal Research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"101"}}